AZ/MedImmune's FluMist gets big boost with new indication

Share this article:
MedImmune announced that the FDA has approved the use of its FluMist in children 2-5 years old, an indication that significantly expands the market for the nasal vaccine.

The company, which AstraZeneca acquired for $15.6 billion in June, had initially seen disappointing returns on the product, approved in 2003 for patients ages 5-49, due to its onerous storage requirements and its age restrictions – the very young and old being the most vulnerable to influenza. It brought in a meager $36.4 million last year.

However, the company won approval for a new formulation that could be stored refrigerated instead of frozen early this year, and now, with access to one of the prime markets for flu vaccines, the product's prospects are looking brighter.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.